The S&P Pharma Dose - Pharmacy Benefit Manager Industry In 2020: Less Regulatory Overhang, Expect More Consolidations | S&P Global Ratings

Name: The S&P Pharma Dose - Pharmacy Benefit Manager Industry In 2020: Less Regulatory Overhang, Expect More Consolidations
Uploaded: 2020-01-21T19:01:18.000Z
Duration: T10M24S
Description: In this episode of S&P Pharma Dose, Ji Liu, Deep Banerjee and Andy Sookram discuss the annual PBM outlook report along with their view on high-profile issuers UnitedHealth, Cigna, CVS and Rite Aid.

In This List

The S&P Pharma Dose - Pharmacy Benefit Manager Industry In 2020: Less Regulatory Overhang, Expect More Consolidations

COMMENTS

China GRE Ratings List

Leveraged Finance & CLOs Uncovered Podcast: Merlin’s Credit Story

COMMENTS

Global Tariff Tracker: Rating Actions As Of May 16, 2025

COMMENTS

U.S. Film And Television Brief: Will 100% Tariffs On Movies Made Outside The U.S. Hurt Hollywood?

21 Jan, 2020 | 12:00

Listen: The S&P Pharma Dose - Pharmacy Benefit Manager Industry In 2020: Less Regulatory Overhang, Expect More Consolidations

Author Ji Liu
Sector Healthcare & Pharmaceuticals
Tags United States of America

In this episode of S&P Pharma Dose, Ji Liu, Deep Banerjee and Andy Sookram discuss the annual PBM outlook report along with their view on high-profile issuers UnitedHealth, Cigna, CVS and Rite Aid.

Author
Ji Liu
Sector
Healthcare & Pharmaceuticals
Tags
United States of America

Create a free account to unlock the article.

Gain access to exclusive research, events and more.

Already have an account? Sign in